| Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. | |
| | |
MedLine Citation:
|
PMID: 12172301 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
For almost 40 years since its discovery in 1953, the mineralocorticoid hormone, aldosterone, was considered to affect blood volume, and thus blood pressure, by its action to retain sodium at epithelial tissues. Over the past decade, direct effects of aldosterone on the heart and blood vessels, and on the cerebral control of blood pressure, have been established in experimental animals. Simultaneously, the incidence of primary aldosteronism in essential hypertension is now acknowledged to be 10-20%, rather than <or= 1%, underscoring a previously unrecognized role for aldosterone in hypertension. The 30% improvement in mortality (and 35% in morbidity) seen in the RALES trial with the addition of low-dose spironolactone to best practice therapy in moderate to severe heart failure, similarly points to an unrecognized role for aldosterone in the pathophysiology of heart failure. Currently, both experimental and clinical studies are directed towards establishing the mechanisms involved in these pathophysiological effects of aldosterone in the cardiovascular system, and of the role of mineralocorticoid receptor antagonists in offsetting or blocking such effects. A brief account of the current state of these mechanisms in at a cellular and tissue level forms the basis of this review. |
| | |
Authors:
|
Morag J Young; John W Funder |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of hypertension Volume: 20 ISSN: 0263-6352 ISO Abbreviation: J. Hypertens. Publication Date: 2002 Aug |
Date Detail:
|
Created Date: 2002-08-12 Completed Date: 2003-02-06 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8306882 Medline TA: J Hypertens Country: England |
Other Details:
|
Languages: eng Pagination: 1465-8 Citation Subset: IM |
Affiliation:
|
Prince Henry's Institute of Medical Research and Baker Medical Research Institute, Melbourne, Australia. morag.young@med.monash.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone
/
physiology* Aldosterone Antagonists / therapeutic use Animals Cardiomegaly / etiology, physiopathology Cardiovascular System / physiopathology* Heart Failure / drug therapy Humans Hyperaldosteronism / complications, physiopathology Hypertension / etiology, physiopathology Receptors, Mineralocorticoid / antagonists & inhibitors, physiology* Spironolactone / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/Receptors, Mineralocorticoid; 52-01-7/Spironolactone; 52-39-1/Aldosterone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Toxic epidermal necrolysis after phenytoin usage in a brain trauma patient.
Next Document: Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials.